National Harbor, MD – Day 2 of #SITC17 brought some interesting highlights on a number of fronts, not all of which may be apparent at present, but there are a few readouts that will have a broader impact going forward.
SITC 2017 Stars?
As we move into an era where we see more combinations evolve in immuno-onology, things are likely to get more confusing rather than less so and it could well be another 3-5 years before things truly settle down and more concrete trends emerge.
Here, we reviewed 10 different areas of interest with a strong clinical relevance and explored the topics further.
Please note that some of these will also have follow-on posts with thought leader interviews and related poster reviews.
To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
With the annual meeting of Society for Immunotherapy of Cancer (SITC) fast approaching this week, it’s time for a look at some of the final highlights to watch out for.
In this latest conference preview, we have chosen a dozen key topics of interest that readers may find worth checking out plus an honourable mention for early compounds in development that we may well hear more about going forward.
Some of the early warning signs were offered up in the earlier Previews and with the abstracts now available, things are getting very interesting indeed…
How are things panning out so far with the abstract drop and are the new products in development living up to the hype and expectations?
To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.
Traditionally we’ve seen the evolution of oncology companies with chemotherapies, then those with targeted therapies, whether TKIs or antibodies.
Increasingly, we’re seeing the rise of an entirely new empire – those with a raft of immunotherapies in their pipeline.
Gems from #ASCO17 Poster Halls
Then there are those with a more mixed portfolio approach of targeted compounds and novel immunotherapy agents… which leads to some interesting combination approaches that target the cancer immunity cycle and address issues that exert inhibitory factors dampening down the immune system responses.
Our latest fireside chat and expert interview focuses on an up and coming biotech company with a pipeline that combines protein targeted antibodies with novel approaches that can potentially reprogram various immune cells in the tumour microenvironment.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.